FINWIRES · TerminalLIVE
FINWIRES

BMOは、オンタリオ州の住宅所有者にとって「さらに厳しいニュース」として、「売れ残った新築マンションの膨大な在庫」を挙げた。

By

-- モントリオール銀行(BMO)は、3月の既存住宅販売統計がオンタリオ州の住宅所有者、特にトロント・ハミルトン大都市圏の住宅所有者にとって「さらに厳しいニュース」をもたらしたと、前日のレポートで述べた。同地域では価格調整が5年目に突入している。 その理由の一つは、売れ残った新築マンションの「膨大な在庫」であり、2025年第4四半期時点で長期平均を40%も上回っていると、同行は指摘した。 「金利が横ばい状態にあるため、この供給過剰を解消する唯一の迅速な方法は、価格引き下げ、場合によっては大幅な引き下げとなるだろう。なぜなら、現在では中間所得層の人々がほぼ手の届く価格帯にある、はるかに安価な中古住宅市場との競争が激化しているからだ」とBMOは述べた。 BMOは、2025年第4四半期の新築マンションの平均価格は1平方フィートあたり1,344ドルで、平均中古価格757ドルを78%、つまり587ドル上回っていると指摘した。この価格差は、10年前のわずか31%、つまり144ドルから「膨れ上がっている」。 BMOは、最近導入された新築マンションに対する最大13%(1平方フィートあたり約175ドル)のHST(統一売上税)還付制度は、価格差を正常化するものではないものの、少なくとも建設業者が供給過剰を解消するのに役立つだろうと付け加えた。

Related Articles

Treasury

Scotiabank Previews This Week's February and Preliminary March GDP for Canada

Canada reports gross domestic product for February and the preliminary estimate for March on Thursday, said Scotiabank.February was initially guided by Statistics Canada to have been tracking a 0.2% month-over-month gain last month. Updated estimates are still in the same ballpark, but investors also get important details on sector drivers, noted the bank.More meaningful may be the flash guidance, with no details, for March GDP, for which there is very little information so far, but a small gain is "feasible," stated Scotiabank.The outcome will further inform Q1 GDP growth tracking on a production/income basis using monthly GDP. It's feasible that growth is tracking close to the Bank of Canada's 1.8% January Monetary Policy Report estimate, but that's on an expenditure basis. The massive over 4% inventory drag on Q4 GDP could reverse as an added upside, pointed out the bank.One key is that consumer spending on goods is tracking a strong rebound in Q1 based on retail sales volumes. It's untrue that the economy isn't exhibiting rate sensitivity, a view that is disproportionately driven by a false understanding of what's keeping condo markets weak in Toronto and Vancouver, added Scotiabank.

$$CXY
Australia

Vicor Insider Sold Shares Worth $2,079,226, According to a Recent SEC Filing

Alvaro Doyle, Vice President and Chief Information Officer, on April 23, 2026, sold 8,000 shares in Vicor (VICR) for $2,079,226. Following the Form 4 filing with the SEC, Doyle has control over a total of 42 common shares of the company, with 42 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/751978/000182673026000002/xslF345X05/primary_doc.xmlPrice: $265.29, Change: $-8.24, Percent Change: -3.01%

$VICR
Australia

BioMarin Seen Building Broader Rare-Disease Platform After Amicus Deal, Morgan Stanley Says

BioMarin Pharmaceutical (BMRN) is emerging as a broader rare-disease platform as its acquisition of Amicus Therapeutics (FOLD) adds two approved medicines and reduces reliance on Voxzogo, Morgan Stanley said Monday in a report.The Amicus deal reshapes BioMarin's outlook by adding Galafold and Pombiliti with Opfolda, products that fit the company's global commercial network, the report said. The therapies are expected to generate more than $1.3 billion in revenue by 2030, Morgan Stanley said.The acquisition is projected to accelerate revenue growth immediately after closing and to be accretive to non-GAAP earnings within 12 months, with "substantial accretion" beginning in 2027, the report said. BioMarin closed its $4.8 billion purchase of Amicus on Monday.Morgan Stanley resumed coverage on BioMarin stock with an overweight rating and a $120 price target.Price: $54.08, Change: $+0.90, Percent Change: +1.68%

$BMRN$FOLD